Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection

Yotam Bronstein; Amos Adler; Haytham Katash; Ora Halutz; Yair Herishanu; Katia Levytskyi

doi:10.1002/jmv.27445

Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection

Yotam Bronstein^*, Amos Adler, Haytham Katash, Ora Halutz, Yair Herishanu, Katia Levytskyi

^*Corresponding author for this work

Tel Aviv University

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Immunocompromised patients have an increased risk of persistent COVID-19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti-SARS-CoV-2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody-resistant SARS-CoV-2 infections evolution in immunocompromised patients.

Original language	English
Pages (from-to)	1241-1245
Number of pages	5
Journal	Journal of Medical Virology
Volume	94
Issue number	3
DOIs	https://doi.org/10.1002/jmv.27445
State	Published - Mar 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jmv.27445

Cite this

@article{7b76a08fad6b4c469d46815de180aed9,

title = "Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection",

abstract = "Immunocompromised patients have an increased risk of persistent COVID-19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti-SARS-CoV-2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody-resistant SARS-CoV-2 infections evolution in immunocompromised patients.",

author = "Yotam Bronstein and Amos Adler and Haytham Katash and Ora Halutz and Yair Herishanu and Katia Levytskyi",

note = "Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",

year = "2022",

month = mar,

doi = "10.1002/jmv.27445",

language = "אנגלית",

volume = "94",

pages = "1241--1245",

journal = "Journal of Medical Virology",

issn = "0146-6615",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection

AU - Bronstein, Yotam

AU - Adler, Amos

AU - Katash, Haytham

AU - Halutz, Ora

AU - Herishanu, Yair

AU - Levytskyi, Katia

PY - 2022/3

Y1 - 2022/3

N2 - Immunocompromised patients have an increased risk of persistent COVID-19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti-SARS-CoV-2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody-resistant SARS-CoV-2 infections evolution in immunocompromised patients.

AB - Immunocompromised patients have an increased risk of persistent COVID-19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti-SARS-CoV-2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody-resistant SARS-CoV-2 infections evolution in immunocompromised patients.

UR - http://www.scopus.com/inward/record.url?scp=85118928951&partnerID=8YFLogxK

U2 - 10.1002/jmv.27445

DO - 10.1002/jmv.27445

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 34755363

AN - SCOPUS:85118928951

SN - 0146-6615

VL - 94

SP - 1241

EP - 1245

JO - Journal of Medical Virology

JF - Journal of Medical Virology

IS - 3

ER -

Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this